- Home
- APLM vs IMRN Comparison
APLM vs IMRN Comparison
Compare APLM & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- IMRN
- Stock Information
- Founded
- APLM 2016
- IMRN 1994
- Country
- APLM United States
- IMRN Australia
- Employees
- APLM N/A
- IMRN N/A
- Industry
- APLM Blank Checks
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- IMRN Health Care
- Exchange
- APLM Nasdaq
- IMRN Nasdaq
- Market Cap
- APLM 15.6M
- IMRN 15.0M
- IPO Year
- APLM N/A
- IMRN N/A
- Fundamental
- Price
- APLM $9.75
- IMRN $1.96
- Analyst Decision
- APLM Strong Buy
- IMRN Strong Buy
- Analyst Count
- APLM 2
- IMRN 1
- Target Price
- APLM $425.00
- IMRN $5.00
- AVG Volume (30 Days)
- APLM 102.2K
- IMRN 6.0K
- Earning Date
- APLM 02-15-2025
- IMRN 12-31-2024
- Dividend Yield
- APLM N/A
- IMRN N/A
- EPS Growth
- APLM N/A
- IMRN N/A
- EPS
- APLM N/A
- IMRN N/A
- Revenue
- APLM $2,101,000.00
- IMRN $3,271,194.00
- Revenue This Year
- APLM N/A
- IMRN N/A
- Revenue Next Year
- APLM N/A
- IMRN N/A
- P/E Ratio
- APLM N/A
- IMRN N/A
- Revenue Growth
- APLM 70.54
- IMRN 171.67
- 52 Week Low
- APLM $6.50
- IMRN $1.59
- 52 Week High
- APLM $105.00
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- APLM 50.39
- IMRN 45.89
- Support Level
- APLM $7.23
- IMRN $2.05
- Resistance Level
- APLM $8.88
- IMRN $2.23
- Average True Range (ATR)
- APLM 1.37
- IMRN 0.17
- MACD
- APLM 0.21
- IMRN -0.00
- Stochastic Oscillator
- APLM 57.91
- IMRN 29.69
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.